Sugi Predict

Sugi Predict / Compounds / SCHEMBL207375

SCHEMBL207375

SCHEMBL207375

[CH2]CNS(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN1A P35498 2/20 0.59
▸ SCN2A Q99250 2/20 0.59
▸ SCN3A Q9NY46 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ CA1 P00915 1/20 0.52
▸ CA2 P00918 1/20 0.52
▸ CA9 Q16790 1/20 0.52
▸ F2 P00734 1/20 0.51
▸ PRSS1 P07477 1/20 0.51
▸ PRSS2 P07478 1/20 0.51
▸ PRSS3 P35030 1/20 0.51
▸ GBA1 P04062 1/20 0.51
▸ SLC6A9 P48067 4/20 0.50
▸ HCRTR1 O43613 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006634 0.84 CYP3A4 (0.69) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL6006630 0.82 SCN1A (0.59) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL2878189 0.82 SCN1A (0.59) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL7906849 0.81 KDM4E (0.59) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL607517 0.81 CYP3A4 (0.66) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL2371351 0.79 CA1 (0.57) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL6006413 0.79 CYP3A4 (0.64) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL3680789 0.79 CYP3A4 (0.64) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL8645259 0.79 SCN1A (0.56) SCN1ASCN2ASCN3AKDM4EALDH1A1
SCHEMBL4263470 0.79 CYP3A4 (0.78) SCN1ASCN2ASCN3AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105085436-B Sulfonic acid amide derivatives and its application on drug 广东东阳光药业有限公司 2019-08-16 — — CN disclosed
CN-102002059-B Process for producing thiazole derivative DAIICHI SANKYO CO LTD 2012-06-13 — — CN disclosed
EP-2431370-A1 Monoacylated 1,2-diaminocycloalkanes DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2012-03-21 — — EP disclosed
CN-101914107-B Process for producing thiazole derivative DAIICHI SEIYAKU CO 2012-03-07 — — CN disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 — — US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 — — US disclosed
US-8058440-B2 Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-11-15 — — US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 — — EP disclosed
US-7935824-B2 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-05-03 — — US disclosed
CN-102002059-A Process for producing thiazole derivative DAIICHI SEIYAKU CO 2011-04-06 — — CN disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 — — US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 — — US disclosed
US-20040122063-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-24 — — US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 — — EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 — — EP disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 — — EP disclosed
US-5274082-A A mono- or diaminonaphthalenepolycarboxylic acid as the chelating compound NIHON MEDI-PHYSICS CO., LTD. (JP) 1993-12-28 — — US disclosed
US-5196576-A Medical imaging of liver tissue NIHON MEDI-PHYSICS CO., LTD. (JP) 1993-03-23 — — US disclosed
US-5138039-A Diagnosis, therapy NIHON MEDI-PHYSICS CO., LTD (JP) 1992-08-11 — — US disclosed
EP-0451824-A2 Chelating compounds and their use NIHON MEDI-PHYSICS CO., LTD. (JP) 1991-10-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020645-A1 Diamine derivatives C9, C1S, C1R SCN1A 645/4885SCN2A 1328/4885SCN3A 1497/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R SCN1A 645/4885SCN2A 1328/4885SCN3A 1497/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R SCN1A 759/4885SCN2A 1550/4885SCN3A 1593/4885
US-20040122063-A1 Ethylenediamine derivatives ECE1, F2, ECE2 SCN1A 1140/4885SCN2A 2075/4885SCN3A 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.